On Jan. 27, 2025, Pure Health has agreed to acquire a 60% stake in Hellenic Health Care Group (HHG). The transaction values. 2.3 billion at USD. Pure Health is the largest healthcare group in the Middle East. Hellenic Health Care Group is the largest private healthcare provider in Greece and Cyprus. Pure Health Partnering with … Read more
JP Morgan Week featured notable developments in drugs, devices, diagnostics, and digital health. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies, bolstering its neuroscience portfolio with CAPLYTA® and a strong mental health pipeline. Eli Lilly invested $2.5 billion in Scorpion Therapeutics’ PI3Kα inhibitor for hormone-positive breast cancer, while Bausch + Lomb expanded ophthalmology with … Read more
Eli Lilly kicked off the 2025 J.P. Morgan Healthcare Conference with a strategic acquisition of Scorpion Therapeutics, securing its PI3Kα pipeline for up to $2.5 billion in upfront payments and milestones. The deal marks a bold move in Lilly’s quest to compete with Novartis and Roche in the lucrative breast cancer market. A Renewed Push … Read more
On Monday, Johnson & Johnson (J&J) made headlines at the J.P. Morgan Healthcare Conference by announcing its agreement to acquire Intra-Cellular Therapies, a pioneering biotech company specializing in treatments for brain diseases. The deal, valued at $132 per share or approximately $14.6 billion, marks the largest biotechnology acquisition since early 2023. A Strategic Play in … Read more
Britan-based pharmaceutical giant GSK has agreed to acquire 100% of the outstanding equity interests (including all options and other incentive equity) in IDRx, a US-based, clinical-stage biopharmaceutical company focused on developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). The acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) being developed … Read more
In early 2025, significant developments across the biopharmaceutical and medical device sectors shaped the healthcare landscape. Stryker’s $4.9 billion acquisition of Inari Medical, Transcarent’s $621 million deal for Accolade, and several FDA designations for investigational treatments, such as Johnson & Johnson’s nipocalimab, highlight industry advancements. Medicare’s rescinding of coverage for certain cancer genetic tests and … Read more
Welcome to this week’s Regulatory Insights from Synopulse, featuring the latest updates from the FDA, EMA, and other global regulatory authorities. From groundbreaking drug approvals to critical recalls and new designations, we cover the most significant events driving the pharmaceutical sector. This comprehensive report offers a concise view of the regulatory milestones shaping the pharma, … Read more
Transcarent has announced plans to acquire Accolade for $621 million, marking a significant step toward its mission of delivering affordable and high-quality healthcare solutions. The acquisition will combine Transcarent’s innovative WayFinding and care solutions with Accolade’s personalized healthcare platform, creating a unified and comprehensive healthcare experience for users. This collaboration aims to enhance accessibility to … Read more